Kimball Electronics Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of Helvoet Polymer Technologies for EUR 90 million expands medical manufacturing capabilities, strengthens the global footprint in Europe and India, and is expected to be accretive to earnings by fiscal 2027. Integration is underway, with immediate focus on synergies and growth opportunities.
-
Q3 saw sequential sales growth led by medical, with margins stable and cash flow positive for the ninth straight quarter. Guidance for FY26 is affirmed, with medical expected to drive further growth as new facility investments ramp up.
-
Revised summary: The company is accelerating its shift toward healthcare, highlighted by a new facility and strong medical segment growth. Full-year guidance was raised on robust demand, with margin improvements from operational discipline and portfolio optimization. Long-term goals include global expansion, deeper customer ties, and higher margins.
-
Q2 sales declined 5% year-over-year to $341 million, with strong medical growth offset by automotive and industrial declines. Margins improved, cash flow remained positive, and guidance for fiscal 2026 was raised on medical and European automotive strength.
-
Q1 FY2026 saw a 2% sales decline but strong margin and net income growth, led by the medical segment. Guidance for FY2026 is reiterated, with continued focus on medical expansion, disciplined capital allocation, and margin improvement despite tariff and market headwinds.
Fiscal Year 2025
-
A global manufacturer is prioritizing growth in its medical segment, leveraging strong customer relationships, a new Indianapolis facility, and a focus on high-complexity, high-margin products. The company is redeploying capital from other segments and pursuing both organic and inorganic expansion, aiming to capitalize on industry trends toward outsourcing.
-
A global electronics manufacturer is focusing on long-term customer relationships, operational excellence, and strategic expansion into the medical CMO market. Despite recent revenue declines and program losses, the company is investing in a new Indianapolis facility and expects a return to growth by FY27.
-
Q4 saw sequential sales growth, margin improvement, and strong cash flow, with the medical segment expanding and a new Indianapolis facility set to drive future growth. FY26 guidance anticipates flat to slightly lower sales, stable margins, and continued investment in medical CMO capabilities.
-
Q3 sales declined year-over-year but improved sequentially, with strong cash flow and reduced debt. Medical sales rose on a one-time consignment, while automotive and industrial segments declined. Guidance for FY25 is reiterated at the high end, with ongoing investments in medical CMO and continued cost controls.
-
Q2 sales fell 15% year-over-year, with broad-based softness across all verticals, but strong cash flow, reduced debt, and inventory improvements strengthened the balance sheet. FY2025 guidance was lowered, and strategic restructuring continues amid tariff and demand uncertainties.
-
Q1 sales fell 15% year-over-year amid broad end-market weakness, but strong cash flow enabled debt reduction and inventory cuts. Facility closure and restructuring aim to boost efficiency, with margin improvement expected later in FY25.
Fiscal Year 2024
-
A global EMS provider reported $1.7B in FY 2024 sales, with FY 2025 guidance down 8–14% due to demand softness and program losses. Strategic focus includes automation, medical sector growth, and capital allocation to debt reduction and share repurchases.
-
Q4 net sales fell 13% year-over-year amid broad demand weakness, but inventory was reduced by 25% and liquidity improved following the AT&M divestiture. Fiscal 2025 sales are expected to decline 8%-14%, with cost control and capital allocation remaining key priorities.
-
The company is navigating a challenging EMS market with proactive cost management, maintaining strong global customer relationships and a focus on high-growth verticals like automotive and medical. Recent capacity expansions and disciplined capital allocation position it for long-term growth despite near-term headwinds.